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Throughout February and March 2020, the COVID-19 pandemic generated shock 
waves worldwide as hospitals struggled to provide the required medical personal 
protective equipment (PPE) to safeguard their staff and emergency personnel. 
Fragile medical logistics infrastructure only exacerbated the crisis. Changes to 
medical supply chains had transformed almost unnoticeably in the quest for low-
cost suppliers and rested on precarious single-source international manufacturing 
centers. Multinational companies dominated discussions as countries and 
politicians shifted attention and resources internally while instituting protectionism 
and threats to restrict foreign sales. Around the world, many governments continue 
to review the existing logistics framework and stockpiling standards to streamline 
processes and prevent a repeat in the future. 
This essay will highlight some of the challenges of contemporary medical 
supply chains, specifically PPE such as face masks, surgical gloves, and medical 
gowns. The focus is primarily on masks, with the 3M company serving as a case 
study. This paper will review three proposed alterations to the existing system and 
the costs and benefits associated with each to improve PPE logistics infrastructure. 
They are as follows: multi-nodal production sites for critical materials located in 
different geographic regions, government-coordinated public-private partnerships 
to map crucial medical supply chain networks, and establishing trusted partners. 
Rather than creating tariffs and more stringent regulations in the medical supply 
industry, this paper argues that a loosening of American trade would better establish 
a global cooperative framework to lessen the impact of a crisis in the future. The 
U.S. government should remove barriers and encourage companies to promote 
transparent supply chains and identify potential choke points and risks while 
creating backup systems to support distribution when disaster strikes. Medical and 
other critical global supply chains must be multimodal with manufacturing sites in 
different countries. These changes will help alleviate the loss of life in the future as 
much as is practicable.  
American Protectionism? 
Protectionism is not new to this country. U.S. trade history has waffled back and 
forth between eliminating trade barriers and imposing tariffs and quotas to prevent 
other countries from accessing American markets. In 1776 Adam Smith advocated 
free markets, with protectionism—famously advocated by Alexander Hamilton—
shortly after that. Hamilton’s exhaustive Report on the Subject of Manufactures 
(1791) was later incorporated into Henry Clay’s Whig party platform under the 
phrase the “American System” and served as the foundation for protectionist 
policies since the early days of the American Republic; Hamilton argued that there 
were natural disadvantages to beginning new industries. Congress eventually 
adopted most of the tariffs cited in the report in 1792, although many of the 
recommendations were not implemented (Irwin, 2020). While the previous Trump 
administration raised the specter of protective tariffs and started a trade war with 
China, the COVD-19 pandemic further exacerbated an already strained 
relationship. The Trump administration’s protectionist response created frictions in 
the global supply chain while highlighting the interconnected nature of 
international medical PPE manufacturers. It is well established that open markets 
and minimal taxes are better methods to stimulate economic development. 
Nevertheless, key or critical industries—such as telecommunications and 
defense—might represent an exception.  
Protectionism and tariffs would harm the medical supply chain. Meredith 
Broadbent, a senior advisor for the Center for Strategic and International Studies 
(CSIS), recently wrote, “Our view is that extensive reshoring and nationalization 
policies would present many costs and added risks. Several case studies support 
this conclusion” (2020, p.7). External controls directly manufacturing into America 
inserts mechanisms that work against free and open markets. There are many 
examples in the pharmaceutical industry, for example, where Canadian and 
American companies cooperate on shared research that only strengthens domestic 
manufacturing. Pfizer’s success with the COVID-19 vaccine was primarily defined 
by its ability to utilize the international market to maximize research, 
manufacturing, and distribution while also collaborating with BioNTech SE in 
Europe (Broadbent, 2020, p.17). 
Supply chains 
While the United States maintains stockpiles of essential commodities such as 
crude oil and some medical supplies, the pandemic revealed that America’s system 
contained  insufficient quantities of surgical masks and also contained discontinued 
items that were unable to be stocked due to oversight. One example is the 
discontinued 3M triple-layer molded face masks required to support the medical 
infrastructure (FDA.gov). A recent study conducted by the McKinsey Global 
Institute (MGI) projected that every 3.7 years, disruptions lasting over 30 days 
would become the norm; the potential causes would vary widely from severe 
climate stress, pandemics, trade disputes, cyber-attacks, terrorism, as well as 
supplier bankruptcy (Lund et al., 2020). In other words, interruptions in logistics 
supply chains will be part of the modern globalized world’s fabric. The financial 
costs will be significant, even jeopardizing the viability of some companies that 
cannot weather the storm.  
Shortages of PPE were very common worldwide, despite the extensive 
stockpiles in countries, such as America, accustomed to large-scale disasters. As of 
September 2020, the U.S. government provided 92.4 million N95 respirators, 
although the Federal Emergency Management Agency (FEMA) reported that there 
were over 6 million N95 requests from state and local governments unfilled as of 
August 4, 2020; suppliers were projected to meet demands in January 2021 
(Broadbent, 2020, p. 15). The onset of COVID-19 caught the United States flat-
footed with gross shortages of medical supplies and insufficient medical 
infrastructure to meet sharp increases in demand.  
The supply of medical equipment, particularly PPE, is complex and opaque. 
It took some time for U.S. leaders to realize that only a few countries provided most 
of America’s PPE, with China being the largest supplier (Broadbent, 2020, p. 10). 
As reality sank in, American leaders, determined to focus on products manufactured 
in the continental United States, quickly discovered the complexity of modern 
logistics supply chains with few domestic manufacturing facilities. In the 21st  
century, supply value chains are spread globally, maximizing low-cost labor in 
regions worldwide, propelling the value of intermediately traded goods to over $10 
trillion (U.S.) annually as of 2020 (Lund et al., 2020). 
The pandemic challenged infrastructure everywhere, and lessons learned are still 
accumulating. Recently Shannon K. O’Neil (2021) wrote in Foreign Affairs: “The 
COVID-19 pandemic has revealed the risks posed by the global concentration of 
production sites for even relatively mundane goods such as ventilators, personal 
protective equipment, and pharmaceutical ingredients; last March, the United 
Kingdom had just a few weeks’ worth of aspirin left within its borders” (pp. 154-
55). The 2020 pandemic prompted all countries to reexamine their policies, 
generating conversations between the private and public arenas in all industries 
worldwide to prevent shortages in the future. Supply practices that promote “just-
in-time” deliveries are being examined, generating reduced overhead warehousing 
costs, creating smaller inventories, and minimizing stockpiles of goods. It appears 
that the most efficient and low-cost systems might not always be the best choice in 
the post-pandemic world.  
The future of supply chains 
MGI published a report in August 2020 that outlined the risk of global supply 
chains across all industries while demonstrating a new trend whereby “only 13 
percent of globally traded goods are now exported from low-wage to high-wage 
countries” (Lund et al., 2020). In other words, China, for example, used to export 
more goods than it consumed internally, but that is no longer the case due to their 
growing middle class. However, China is still the world’s factory, with more and 
more consumer goods staying within its borders than leaving. Low-cost skilled 
labor continues to drive economic decisions for all companies. Yet, these 
considerations are balanced with shipment speed, location to major markets, 
resource availability, and resilience for logistics infrastructure. Although 
demographic changes continue to alter the landscape for medical logistics, it helps 
depict the existing supply network. 
After the outbreak of COVID-19, global shortages of PPE, specifically face 
masks, revealed strategic miscoordination in policies of the U.S. government and 
the American company 3M. Based in Minnesota, 3M is a top American 
manufacturer of M95 face masks and supplier for many industries and countries 
worldwide, with factories in both the United States and China. Before the 
pandemic, the monthly production of M95 masks was 35 million, although only 5 
million remained in the United States, with most exported internationally (Gereffi, 
2020). The company anticipated an increased demand signal and increased 
production across all locations in early 2020. Even so, the Trump administration 
quickly criticized them for putting other countries ahead of American healthcare 
workers. As Gary Gereffi (2020) noted, the “waves of economic nationalism and 
populism since 2016, and the COVID-19 pandemic in 2020 all portend a more 
fragmented, multipolar, and regionally oriented international system. While 
effective forms of globalization are likely to be the most constructive and 
sustainable response in the post-crisis era, de-globalization is not a viable long-term 
vision for the future” (Ibid.).  
Protectionist reactions 
On April 2, 2020, an executive order cited the Defense Production Act (DPA) from 
1950 to force 3M to stop exporting N95 masks (Gereffi, 2020). Lawyers at 3M 
highlighted the nature of integrated markets and globalized supply systems 
contingent upon imports from other countries that would reciprocate, leading to a 
deterioration of desperately required medical supplies in the market (Gereffi, 2020). 
Reluctantly, and somewhat surprisingly, White House supply chain coordinator 
Peter Navarro relented, allowing 3M to continue exporting. The crisis was averted, 
and other countries, notably China, were poised to reciprocate and backed off. The 
company rapidly stepped up production, doubling its global capacity to over 2 
billion masks by the end of 2020 (Gereffi, 2020). The lessons learned from 
Hurricane Maria are also helpful in the need for multiple sources for medical 
supplies. When the hurricane hit Puerto Rico in 2017, hospitals quickly exhausted 
supplies and drugs while the island struggled to provide essential medical services. 
It appears that medical supply chains operate best only “when any single company 
or country doesn’t dominate production. Indeed, Washington may find that 
strengthening access to critical goods means more, rather than less, international 
collaboration” (O’Neil, 2021, p. 157). 
The ability exhibited by 3M to rapidly expand production represents an 
American success story, but it also demonstrates policy failures and a lack of 
understanding of supply systems. Just-in-time or on-demand manufacturing 
systems drove skeletal systems that reduced waste and global inventories. 
Simultaneously, transportation costs and accessibility to other markets 
decentralized production facilities, allowing greater scalability given the 
decentralized nature of some manufacturing processes, albeit relying on external 
suppliers and labor often in other countries. The 3M case also demonstrates the 
importance of maintaining multiple production sites and runs counter to arguments 
advocating locating critical manufacturing, particularly products deemed “crucial” 
within the United States, or any other country for that matter. While it is necessary 
to increase domestic production for PPE, there is also a strong need to maintain 
open markets without imposing tariffs; this allows operations to flow naturally in 
regions more beneficial for production costs. Excessive regulation would have 
further exacerbated the impact of COVID-19 and must serve as a lesson for 
politicians going forward.  
Supply chain mapping 
The pandemic demonstrated that a single-source global supply chain for supplies 
and pharmaceuticals could not keep up with the demand for a planet with almost 8 
billion people, even though such systems may produce the lowest cost for 
consumers. Some supply chains might be more complex, and supply chain mapping 
can help provide critical leaders with an overview of material flow to help identify 
resources from high-risk regions of the world. Mapping can be a useful tool in 
identifying alternative sources of supply as well as potential substitutes. 
Distribution disruptions or bottlenecks could trigger alternative pathways for the 
origination and transportation of the requisite resources. The U.S. Department of 
Defense began to map all critical suppliers due to COVID-19 challenges to 
reexamine prime contractors, such as Lockheed Martin and General Dynamics, 
while mapping supplier chains better to understand potential issues in the critical 
defense industry well (Clark 2021). 
 In late 2020, MGI conducted surveys of a broad range of companies and 
found that many organizations—over two-thirds—are beginning to map production 
footprints. They are struggling, however, to understand the financial stability of all 
participants in their value chains (Lund et al., 2020, p. 76). Organizations must 
begin to “work more closely with their tier-one suppliers to create transparency; 
after all, those suppliers are likely to have similar concerns about their vendors. 
However, some may lack visibility themselves or may consider their sourcing to be 
proprietary information” (Lund et al., p. 77). Some companies would risk 
publicizing trade secrets, and their competitors could utilize a heightened 
awareness of their logistics infrastructure.  
Strengthening the supply chain, particularly for companies that manufacture 
PPE, continues to be a priority. In contrast, a recent Gartner survey among medical 
companies conducted in February and March of last year revealed that “only 21 
percent of respondents considered their supply chains to be highly resilient at the 
time of the survey, [and] one-quarter of respondents said they have already begun 
to regionalize or localize supply chains to dampen disruptions and be closer to 
demand” (Broadbent, 2020, p. 6). In the same survey, 55 percent of the company 
supply chain specialists responded that their supply infrastructure would become 
more resilient with shift sourcing, manufacturing, and distribution on demand. It 
would take, however, another two or three years to complete the process 
(Broadbent, 2020, p. 6). End-to-end transparency is helpful. Integrating data into 
the internet can provide real-time data and forecasting to better project material and 
resource availability while monitoring production and transportation flow up and 
downstream from production centers. Digitization and system mapping allow for a 
more comprehensive view of the entire process. However, limited access in remote 
markets from subcontractors still creates grey areas where information is not readily 
available. Increased automation will also reduce labor costs for manufacturing 
while stimulating companies to locate sites domestically (Broadbent, 2020, p. 6).  
Trusted trade partners 
Transparency can help provide improved visibility although the federal government 
will have to work with the United States Trade Representative (USTR) to solidify 
partnerships with Mexico and Canada, along with several other countries, to 
achieve a broad network of manufacturing practices as well as the free flow of 
information to better respond to requirements for PPE in the future. International 
partnerships can provide flexible networks and arrangements to better support allies 
and trusted partners during regional or localized events. In the event of another 
global pandemic, countries will focus on domestic issues first, but complete 
international supply lines and more extensive diverse networks will support trusted 
supply chain partners. 
 North America is an ideal region to establish trusted supplier partnerships 
with Canada to the north and Mexico just south of the United States as 
transportation costs are reduced significantly. The manufacture of medical PPE in 
Canada could serve as a template for future agreements to keep costs low. Similar 
regulatory requirements and standards, which are sometimes obstacles when 
importing items from countries with vastly different manufacturing guidelines, 
would provide better regulatory flexibility and cooperation as well as straightforward 
collaboration in the research and development of new drugs. For example, U.S. 
imports from Canadian for non-medical grade disposable gloves grew by 1000 to 
4500 percent, depending on the material (Broadbent, 2020, p. 8). The USTR should 
lead efforts to streamline trade agreements with other countries interested in 
upgrading trade and investment relationships with the United States if they can 
adhere to acceptable manufacturing practices as established by the Food and Drug 
Administration (FDA) and follow intellectual property requirements. These goods 
and products required for manufacturing PPE would be outside the scope of tariffs 
and import/export restrictions that could create bottlenecks during a crisis. 
Additionally, this oversight will allow for prioritizing raw materials for essential 
goods, which can better support global supply chain requirements.  
Conclusion 
The federal government can assist the USTR by coordinating and sharing 
information between suppliers in different countries to track essential supply 
chains, performing exercises and tests to stress test logistics infrastructure, and 
creating a regulatory environment that is conducive to trade and foreign suppliers 
by promoting transparency and minimal obstacles for external companies. 
International organizations can also help. As O’Neil (2021) recently pointed out,  
Global supply chains are here to stay, and U.S. workers will be left behind 
if American companies can’t take advantage of them. A U.S. industrial 
policy built on more global cooperation and competition, better U.S. access 
to international markets, and public investments at home can mitigate the 
shortcomings of the Washington consensus and avoid the pitfalls of 
protectionism. (p. 151) 
To better prepare for the next crisis in three years, the U.S. should not impose 
restrictive tariffs to burden medical supply industries. The government can get 
involved to remove barriers and encourage companies to promote transparent 
supply chains. We must identify potential choke points and risks while creating 
backup systems to support distribution when disaster strikes. Medical and other 
critical global supply chains must be multimodal with manufacturing sites in 
different countries. These changes will help alleviate the loss of life in the future as 
much as is practicable. The restart of America’s economy offers an opportunity to 
retool the U.S. medical supply chain to reduce vulnerabilities exposed by the 
COVID-19 pandemic and correct other problems. This reset might be fortunate for 
the United States. It will allow time to correct deficiencies and prepare for the next 
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